Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: NAD Decisions, Warning Letters, EC Law Struck, “Natural” Claims Suit

This article was originally published in The Tan Sheet

Executive Summary

Pharmavite discontinues ads; NAD looks at supplement concussion claims; FDA warns product requires NDI; Spinal Touch Formulas are unapproved new drugs – FDA; Weight-loss products unapproved, misbranded; Oklahoma law restricting contraception knocked down; and Hammer Nutrition sued over “natural” claims

You may also be interested in...



Pharmavite Targets More Evidence To Support Challenged Omega-3 Claim

Pharmavite will not follow NAD’s recommendation to discontinue claim its NatureMade Omega 3 Xtra Blend fish oil supplement offers “nearly 4x better absorption” than standard fish oil, but plans another clinical study supporting the statement.

Claims Emerge To Join “Natural” As Class Action Fodder

Claims a product is “natural,” health and prevention claims, “whole grain” and “made with” claims, all can put a firm at risk for a lawsuit, the Center for Science in the Public Interest warns. After climbing for five years in a row, class action lawsuits brought against food products dipped in 2013, but the decline may be short-lived.

Spiked “Supplements” For Diabetes, Pain On The Rise

FDA is seeing supplements spiked with Rx ingredients indicated for pain management and diabetes treatment, and needs industry help identifying violators, CFSAN head Michael Landa says.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel